Symbols / VOR
VOR Chart
About
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to treat patients in VBP101, which is in phase 1 / 2; and VCAR33, a CAR-T therapy designed to target CD33, which is under preclinical studies to treat AML post-transplant. The company also develops trem-cel + VCAR33 treatment system, CD33-directed CAR-T program, which is under pre-clinical studies for the treatment of AML; VADC45 for the treatment of hematologic malignancies, conditioning, and immune reset, which is under preclinical studies; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-edited HSC therapy and a CD33-CLL1 multi-specific CAR-T therapy, which is under preclinical studies for the treatment of AML. It has a license agreement with Columbia University and the National Institutes of Health for patents; and with Editas Medicine, Inc. for ex-vivo Cas9 gene-edited HSC therapies for the treatment and/or prevention of hematological malignancies. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 560.31M |
| Enterprise Value | -32.27M | Income | -2.45B | Sales | — |
| Book/sh | -246.54 | Cash/sh | 16.37 | Dividend Yield | — |
| Payout | 0.00% | Employees | 154 | IPO | — |
| P/E | — | Forward P/E | -2.93 | PEG | — |
| P/S | — | P/B | -0.05 | P/C | — |
| EV/EBITDA | 0.10 | EV/Sales | — | Quick Ratio | 9.05 |
| Current Ratio | 9.16 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -386.86 | EPS next Y | -4.61 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-26 | ROA | -144.27% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 41.52M |
| Shs Float | 7.21M | Short Float | 6.79% | Short Ratio | 2.38 |
| Short Interest | — | 52W High | 65.80 | 52W Low | 2.62 |
| Beta | 2.02 | Avg Volume | 1.80M | Volume | 308.24K |
| Target Price | $44.60 | Recom | None | Prev Close | $12.98 |
| Price | $13.49 | Change | 3.97% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$44.60
Mean price target
2. Current target
$13.50
Latest analyst target
3. DCF / Fair value
$-79.51
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$13.50
Low
$32.00
High
$55.00
Mean
$44.60
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-09 | init | Citigroup | — → Buy | $50 |
| 2025-12-19 | main | JP Morgan | Overweight → Overweight | $40 |
| 2025-12-17 | init | TD Cowen | — → Buy | — |
| 2025-12-09 | init | JP Morgan | — → Overweight | $43 |
| 2025-11-14 | main | HC Wainwright & Co. | Buy → Buy | $32 |
| 2025-10-29 | main | HC Wainwright & Co. | Buy → Buy | $55 |
| 2025-10-15 | up | Baird | Neutral → Outperform | $64 |
| 2025-08-14 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-06-30 | up | HC Wainwright & Co. | Neutral → Buy | $3 |
| 2025-06-27 | main | Baird | Neutral → Neutral | $1 |
| 2025-06-26 | reit | Wedbush | Neutral → Neutral | $0 |
| 2025-05-09 | down | JMP Securities | Market Outperform → Market Perform | $6 |
| 2025-05-09 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2025-03-21 | reit | Oppenheimer | Outperform → Outperform | $8 |
| 2025-03-21 | main | Stifel | Buy → Buy | $5 |
| 2025-03-21 | main | HC Wainwright & Co. | Buy → Buy | $13 |
| 2024-12-10 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2024-12-10 | reit | JMP Securities | Market Outperform → Market Outperform | $12 |
| 2024-11-08 | main | Baird | Outperform → Outperform | $14 |
| 2024-11-08 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
News
RSS: Latest VOR news- Vor Biopharma (NASDAQ:VOR) Stock Price Down 4% - What's Next? - MarketBeat hu, 12 Feb 2026 11
- Vor Biopharma (Nasdaq: VOR) prices 10,000,000-share stock offering for $100M - Stock Titan Mon, 10 Nov 2025 08
- VOR: TD Cowen Initiates Coverage with a 'Buy' Rating | VOR Stock News - GuruFocus Wed, 17 Dec 2025 08
- $VOR stock is down 13% today. Here's what we see in our data. - Quiver Quantitative Wed, 19 Nov 2025 08
- JPMorgan initiates Vor Biopharma stock with Overweight rating on telitacicept potential - Investing.com ue, 09 Dec 2025 08
- Vor Biopharma: J.P. Morgan Makes Bull Case After Corporate Actions Slam Stock Price (VOR) - Seeking Alpha Wed, 10 Dec 2025 08
- Vor Biopharma Earns Relative Strength Rating Upgrade - Investor's Business Daily Wed, 11 Feb 2026 08
- Vor Biopharma (Nasdaq: VOR) commences $100M stock offering; underwriters' option up to $15M - Stock Titan Mon, 10 Nov 2025 08
- $VOR stock is up 13% today. Here's what we see in our data. - Quiver Quantitative ue, 16 Dec 2025 08
- Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why - Yahoo Finance Mon, 30 Jun 2025 07
- Vor Biopharma Earns Relative Strength Rating Upgrade; Hits Key Benchmark - Investor's Business Daily Mon, 09 Feb 2026 08
- Vor Biopharma stock initiated with Buy rating at TD Cowen on promising telitacicept potential - Investing.com Wed, 17 Dec 2025 08
- Vor Bio (Nasdaq: VOR) prices $150M private placement, grants Forbion board seat - Stock Titan Mon, 15 Dec 2025 08
- Vor Biopharma (VOR) Is Up 45.6% After Telitacicept Phase 3 Win And JPMorgan Nod Has The Bull Case Changed? - Yahoo Finance Fri, 12 Dec 2025 08
- VOR Stock Unaffected by Selling Stockholders' Actions - GuruFocus hu, 29 Jan 2026 22
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 400408 | 10368938 | — | Sale at price 25.12 - 28.18 per share. | RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-30 00:00:00 | I |
| 1 | 221166 | 6204863 | — | Sale at price 28.01 - 28.12 per share. | RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-27 00:00:00 | I |
| 2 | 117050 | 3433992 | — | Sale at price 28.11 - 30.12 per share. | RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-21 00:00:00 | I |
| 3 | 37533 | 1133103 | — | Sale at price 30.05 - 31.00 per share. | REPROGRAMMED INTERCHANGE LLC | Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-21 00:00:00 | D |
| 4 | 464025 | 13707361 | — | Sale at price 29.12 - 31.35 per share. | RA CAPITAL HEALTHCARE FUND,L.P. | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-17 00:00:00 | I |
| 5 | 73676 | 2348744 | — | Sale at price 30.45 - 32.77 per share. | REPROGRAMMED INTERCHANGE LLC | Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-16 00:00:00 | D |
| 6 | 96657 | 3003706 | — | Sale at price 30.32 - 33.09 per share. | REPROGRAMMED INTERCHANGE LLC | Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-14 00:00:00 | D |
| 7 | 124146 | 4116369 | — | Sale at price 31.92 - 34.34 per share. | REPROGRAMMED INTERCHANGE LLC | Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-09 00:00:00 | I |
| 8 | 98387 | 3553499 | — | Sale at price 33.84 - 37.77 per share. | REPROGRAMMED INTERCHANGE LLC | Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-07 00:00:00 | D |
| 9 | 41752 | 1646237 | — | Sale at price 37.21 - 42.32 per share. | REPROGRAMMED INTERCHANGE LLC | Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-03 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -117.66M | -122.54M | -90.89M | -67.58M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -116.91M | -117.86M | -92.09M | -68.90M |
| ReconciledDepreciation | 3.53M | 3.49M | 2.52M | 1.43M |
| EBITDA | -117.66M | -122.54M | -90.89M | -67.58M |
| EBIT | -121.19M | -126.04M | -93.42M | -69.02M |
| NetInterestIncome | 4.27M | 8.17M | 1.32M | 119.00K |
| InterestIncome | 4.27M | 8.17M | 1.32M | 119.00K |
| NormalizedIncome | -116.91M | -117.86M | -92.09M | -68.90M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -116.91M | -117.86M | -92.09M | -68.90M |
| TotalExpenses | 121.19M | 126.04M | 93.42M | 69.02M |
| TotalOperatingIncomeAsReported | -121.19M | -126.04M | -93.42M | -69.02M |
| DilutedAverageShares | 3.44M | 3.36M | 1.98M | 1.67M |
| BasicAverageShares | 3.44M | 3.36M | 1.98M | 1.67M |
| DilutedEPS | -34.00 | -35.00 | -46.60 | -42.00 |
| BasicEPS | -34.00 | -35.00 | -46.60 | -42.00 |
| DilutedNIAvailtoComStockholders | -116.91M | -117.86M | -92.09M | -70.13M |
| NetIncomeCommonStockholders | -116.91M | -117.86M | -92.09M | -70.13M |
| PreferredStockDividends | 1.23M | |||
| NetIncome | -116.91M | -117.86M | -92.09M | -68.90M |
| NetIncomeIncludingNoncontrollingInterests | -116.91M | -117.86M | -92.09M | -68.90M |
| NetIncomeContinuousOperations | -116.91M | -117.86M | -92.09M | -68.90M |
| PretaxIncome | -116.91M | -117.86M | -92.09M | -68.90M |
| NetNonOperatingInterestIncomeExpense | 4.27M | 8.17M | 1.32M | 119.00K |
| InterestIncomeNonOperating | 4.27M | 8.17M | 1.32M | 119.00K |
| OperatingIncome | -121.19M | -126.04M | -93.42M | -69.02M |
| OperatingExpense | 121.19M | 126.04M | 93.42M | 69.02M |
| ResearchAndDevelopment | 93.31M | 94.31M | 64.55M | 47.53M |
| SellingGeneralAndAdministration | 27.88M | 31.72M | 28.87M | 21.49M |
| GeneralAndAdministrativeExpense | 27.88M | 31.72M | 28.87M | 21.49M |
| OtherGandA | 27.88M | 31.72M | 28.87M | 21.49M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2021-12-31 | ||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | 10.03K | ||
| OrdinarySharesNumber | 6.24M | 3.39M | 3.30M | 1.86M |
| ShareIssued | 6.24M | 3.39M | 3.30M | 1.87M |
| TotalDebt | 31.83M | 35.66M | 38.91M | 18.01M |
| TangibleBookValue | 96.66M | 150.72M | 250.61M | 216.26M |
| InvestedCapital | 96.66M | 150.72M | 250.61M | 216.26M |
| WorkingCapital | 77.89M | 125.23M | 223.83M | 204.25M |
| NetTangibleAssets | 96.66M | 150.72M | 250.61M | 216.26M |
| CapitalLeaseObligations | 31.83M | 35.66M | 38.91M | 18.01M |
| CommonStockEquity | 96.66M | 150.72M | 250.61M | 216.26M |
| TotalCapitalization | 96.66M | 150.72M | 250.61M | 216.26M |
| TotalEquityGrossMinorityInterest | 96.66M | 150.72M | 250.61M | 216.26M |
| StockholdersEquity | 96.66M | 150.72M | 250.61M | 216.26M |
| GainsLossesNotAffectingRetainedEarnings | 22.00K | -77.00K | -770.00K | 0.00 |
| OtherEquityAdjustments | 22.00K | -77.00K | -770.00K | |
| RetainedEarnings | -456.99M | -340.08M | -222.22M | -130.12M |
| AdditionalPaidInCapital | 553.62M | 490.87M | 473.59M | 346.38M |
| CapitalStock | 13.00K | 7.00K | 7.00K | 4.00K |
| CommonStock | 13.00K | 7.00K | 7.00K | 4.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 46.23M | 47.40M | 48.76M | 26.33M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 27.61M | 31.83M | 35.64M | 16.17M |
| LongTermDebtAndCapitalLeaseObligation | 27.61M | 31.83M | 35.64M | 16.17M |
| LongTermCapitalLeaseObligation | 27.61M | 31.83M | 35.64M | 16.17M |
| CurrentLiabilities | 18.61M | 15.57M | 13.12M | 10.15M |
| OtherCurrentLiabilities | 356.00K | 324.00K | 537.00K | 1.05M |
| CurrentDebtAndCapitalLeaseObligation | 4.21M | 3.83M | 3.27M | 1.84M |
| CurrentCapitalLeaseObligation | 4.21M | 3.83M | 3.27M | 1.84M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 5.85M | 5.96M | 4.41M | 4.18M |
| PayablesAndAccruedExpenses | 8.19M | 5.46M | 4.90M | 3.08M |
| CurrentAccruedExpenses | 6.68M | 4.64M | 3.13M | 1.54M |
| Payables | 1.50M | 815.00K | 1.77M | 1.54M |
| AccountsPayable | 1.50M | 815.00K | 1.77M | 1.54M |
| TotalAssets | 142.89M | 198.13M | 299.37M | 242.59M |
| TotalNonCurrentAssets | 46.38M | 57.32M | 62.42M | 28.19M |
| OtherNonCurrentAssets | 4.80M | 7.22M | 5.34M | 5.67M |
| NetPPE | 41.59M | 50.10M | 57.08M | 22.52M |
| AccumulatedDepreciation | -11.21M | -8.09M | -4.61M | -2.08M |
| GrossPPE | 52.80M | 58.19M | 61.69M | 24.61M |
| Leases | 55.00K | |||
| ConstructionInProgress | 36.00K | 146.00K | 1.04M | 0.00 |
| OtherProperties | 51.71M | 57.01M | 59.65M | 24.29M |
| MachineryFurnitureEquipment | 1.05M | 1.03M | 1.00M | 317.00K |
| Properties | 0.00 | |||
| CurrentAssets | 96.51M | 140.80M | 236.95M | 214.40M |
| OtherCurrentAssets | 380.00K | 475.00K | 2.34M | 2.09M |
| PrepaidAssets | 4.20M | 3.15M | 4.37M | 4.84M |
| CashCashEquivalentsAndShortTermInvestments | 91.93M | 137.18M | 230.25M | 207.47M |
| OtherShortTermInvestments | 9.98M | 105.81M | 172.54M | 87.67M |
| CashAndCashEquivalents | 81.95M | 31.36M | 57.71M | 119.80M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -99.89M | -101.36M | -93.61M | -73.04M |
| IssuanceOfCapitalStock | 55.83M | 4.58M | 115.97M | 234.57M |
| CapitalExpenditure | -229.00K | -1.07M | -8.46M | -3.89M |
| EndCashPosition | 84.36M | 33.77M | 60.12M | 122.21M |
| BeginningCashPosition | 33.77M | 60.12M | 122.21M | 50.10M |
| ChangesInCash | 50.59M | -26.35M | -62.09M | 72.12M |
| FinancingCashFlow | 53.39M | 2.94M | 117.14M | 232.91M |
| CashFlowFromContinuingFinancingActivities | 53.39M | 2.94M | 117.14M | 232.91M |
| NetOtherFinancingCharges | -2.33M | -717.00K | -2.21M | |
| ProceedsFromStockOptionExercised | -108.00K | -923.00K | 1.17M | 553.00K |
| NetPreferredStockIssuance | 0.00 | 45.38M | ||
| PreferredStockIssuance | 0.00 | 45.38M | ||
| NetCommonStockIssuance | 55.83M | 4.58M | 115.97M | 189.20M |
| CommonStockIssuance | 55.83M | 4.58M | 115.97M | 189.20M |
| InvestingCashFlow | 96.86M | 71.01M | -94.09M | -91.65M |
| CashFlowFromContinuingInvestingActivities | 96.86M | 71.01M | -94.09M | -91.65M |
| NetInvestmentPurchaseAndSale | 97.09M | 72.08M | -85.63M | -87.76M |
| SaleOfInvestment | 107.00M | 147.00M | 37.56M | 0.00 |
| PurchaseOfInvestment | -9.91M | -74.92M | -123.19M | -87.76M |
| NetPPEPurchaseAndSale | -229.00K | -1.07M | -8.46M | -3.89M |
| PurchaseOfPPE | -229.00K | -1.07M | -8.46M | -3.89M |
| OperatingCashFlow | -99.66M | -100.29M | -85.14M | -69.14M |
| CashFlowFromContinuingOperatingActivities | -99.66M | -100.29M | -85.14M | -69.14M |
| ChangeInWorkingCapital | 5.00K | 650.00K | -9.84M | -9.19M |
| ChangeInOtherCurrentLiabilities | -3.83M | -3.58M | -10.45M | -2.56M |
| ChangeInOtherCurrentAssets | 2.43M | -1.89M | -721.00K | -668.00K |
| ChangeInPayablesAndAccruedExpense | 2.24M | 2.85M | 1.11M | 405.00K |
| ChangeInPrepaidAssets | -835.00K | 3.27M | 225.00K | -6.36M |
| OtherNonCashItems | 5.04M | 4.73M | 3.58M | 3.19M |
| StockBasedCompensation | 9.85M | 13.36M | 10.70M | 4.32M |
| AmortizationOfSecurities | -1.15M | -4.66M | -12.00K | |
| DepreciationAmortizationDepletion | 3.53M | 3.49M | 2.52M | 1.43M |
| DepreciationAndAmortization | 3.53M | 3.49M | 2.52M | 1.43M |
| Depreciation | 3.53M | 3.49M | 2.52M | 1.43M |
| OperatingGainsLosses | -18.00K | |||
| GainLossOnSaleOfPPE | -18.00K | 0.00 | ||
| NetIncomeFromContinuingOperations | -116.91M | -117.86M | -92.09M | -68.90M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for VOR
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|